Alkermes plc (ALKS)
NASDAQ
Closed
Aug 24, 2026
Day's Range
47.7652 wk Range
25.17Overview - ALKS - Alkermes plc
Key Statistics
Valuation
Enterprise Value
9.02B
P/E (Trailing)
‪127.18‬
P/E (Forward)
‪26.43‬
PEG Ratio
‪-1.27‬
Price / Sales (TTM)
‪4.86‬
Price / Book
‪4.47‬
EV / EBITDA
‪31.67‬
Profitability
Profit Margin
‪3.96%‬
Operating Margin
‪15.49%‬
Return on Assets
‪4.20%‬
Return on Equity
‪3.85%‬
Ownership
Shares Outstanding
167.76M
Float
154.64M
Short % of Shares Outstanding
‪11.89%‬
Held by Insiders
‪1.40%‬
Held by Institutions
‪108.78%‬
Price stats
Beta
‪0.26‬
50-Day Avg
‪50.29‬
200-Day Avg
‪36.89‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
18 analysts
Average price target
‪$ 56.00‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ALKS - Alkermes plc
Peers - ALKS - Alkermes plc
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- ALALKSNASDAQAlkermes plc8.10BMarket Cap+40.00%52-week change127.18P/E (Trailing)‪3.96%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences Inc.15.50BMarket Cap+12.18%52-week change22.34P/E (Trailing)‪20.91%‬Profit Margin
- LNTHNASDAQLantheus Holdings, Inc.6.52BMarket Cap+43.82%52-week change23.92P/E (Trailing)‪17.69%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals Inc.6.23BMarket Cap+48.19%52-week change37.60P/E (Trailing)‪5.04%‬Profit Margin
- KNKNSANASDAQKiniksa Pharmaceuticals International, plc6.16BMarket Cap+58.19%52-week change79.83P/E (Trailing)‪9.59%‬Profit Margin
- ALMNASDAQAlmonty Industries Inc.5.33BMarket Cap+76.82%52-week change84.14P/E (Trailing)‪125.23%‬Profit Margin
- AMLXNASDAQAmylyx Pharmaceuticals, Inc. Common Stock4.41BMarket Cap+76.55%52-week change2.54P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - ALKS - Alkermes plc
About
Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
